Navigation Links
Naviscan Announces European Launch of Positron Emission Mammography
Date:3/2/2011

VIENNA, March 2, 2011 /PRNewswire/ -- Naviscan, Inc., announces the European launch of the Naviscan Positron Emission Mammography (PEM) scanner at two prestigious radiology conferences in Vienna.  On March 3rd, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting, a podium presentation will focus on recently published PEM (Positron Emission Mammography) data demonstrating PEM's ability to reduce unnecessary biopsies by providing superior specificity, the ability to differentiate between benign and malignant lesions.  Simultaneously at the European Congress of Radiology (ECR) conference, March 3 - 7, a poster will be presented featuring new clinical data on the role of PEM for assessment of axillary lymph node (ALN) status in patients with breast cancer.

PEM scanners are high-resolution breast PET systems (also referred to as 3-D Molecular Breast Imagers or Tomographic MBI) that can show the location as well as the metabolic phase of a lesion.  This information is critical in determining whether a lesion is malignant and influences the course of treatment.  PEM scanners, which are about the size of an ultrasound system, are manufactured by Naviscan, Inc. and have been commercially available since 2007.

The poster will highlight new clinical data from researchers at the University of Chicago on the role of PEM for assessment of axillary lymph node status in patients with breast cancer.  Current morphology-based tools for ALN staging include clinical examination, axillary ultrasound and breast MRI, but none are accurate enough to replace the need for pathologic evaluation of the axillary nodes. In this prospective study, 20 newly diagnosed breast cancer patients underwent mammography, breast and axillary ultrasound, breast MRI and PEM.  Suspicious lymph nodes were evaluated and final ALN status was determined via pathology.

The preliminary data show promising results for PEM in accurate lymph node assessment.  PEM demonstrates 88% sensitivity with a negative predictive value of 91% in assessment of ALN status in patients with breast cancer.  The data show improved lesion detectability and decrease in background activity.

"Our study provides additional compelling evidence that PEM can play an important role in axillary staging, perhaps with more sensitivity than ultrasound or MRI," stated Dr. Daniel Appelbaum, Associate Professor of Radiology from The University of Chicago Medical Center.  "Furthermore, these findings, in conjunction with PEM's more extensively documented role in evaluating the breasts themselves as well as whole body PET's excellent whole body staging, paves the way for a complete breast cancer work-up—primary tumor, regional and distant metastases--with one FDG dose."

Naviscan plans to distribute its PEM scanner in Europe in Q2 2011.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PEM scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Naviscan® Announces Collaboration With Neoprobe Corporation to Enable Pipeline Technology Development
2. SightLine Health Adds Naviscan PEM Technology to Breast Cancer Treatment Services
3. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
4. Johns Hopkins Medicine Acquires Naviscan PEM Technology for Novel Radiotracer Research
5. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
6. Baylor Adds Naviscan PEM Technology to Womens Imaging Center
7. CVS Caremark Announces Agreement With ActiveHealth Management for Evidence-Based Clinical Decision Support
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Sangamo BioSciences Announces Presentation at the Cowen and Company 31st Annual Health Care Conference
10. An Easier Way to Breathe Better - ICAP Ocean Tomo Announces an Advanced Medical Inhaler Design
11. Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):